You are here

Novosanis launches Colli-Pee containing UAS Large Volumes offering a new solution for oncology research
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM...
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine.
Novosanis is offering a research grant in collaboration with EACR to stimulate innovative research in cancer biomarker detection using urine as a sample type. Urine can be collected in an...
Novosanis hosted a virtual booth at Eurogin 2021, an international conference focusing on Human Papillomavirus (HPV). Urine, particularly, first-void urine, has potential to screen for...
It is well-established that Human Papillomavirus (HPV), the primary cause of cervical cancer can be detected in first-void urine. The study by Laura Téblick (University of Antwerp, Belgium...
We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp.
What a milestone! 8 years and counting. To celebrate our 8th anniversary, we asked our team members to describe Novosanis and their experience in unique words. Teamwork and Innovation were...
CE-IVD marked
Novosanis achieved two major milestones - our Colli-Pee ® Small Volumes product line is now CE-Marked.
In view of the spread of Covid-19 (coronavirus) in our country and across the world, our topmost priority is the health and safety of all our customers and employees. Our team will be...
Novosanis celebrates 7 years
Today Novosanis Turns 7! On our 7th anniversary, we are proud to share some key highlights.
Eurogin 2019
It's been a few weeks since we've been back from Eurogin 2019. Read our news item sharing a few highlights of our trip and the conference.
First-void urine to detect Chlamydia prevalence in the Belgian population
Researchers at The Sciensano Institute in Belgium will be using urine collected through Colli-Pee ® to understand Chlamydia presence in all ages and genders in the Belgium population.